JPRN-jRCT2080223352未知2 期
Phase II study of BK1304 in healthy adults
The Research Foundation For Microbial Diseases Of Osaka University0 个研究点目标入组 600 人开始时间: 2016年10月20日最近更新:
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Written informed consent is obtained from subject
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Phase III study of BK1304 in healthy adults and adolescentsPrevention of influenzaJPRN-jRCT2080224074The Research Foundation for Microbial Diseases of Osaka University1,500
已完成
2 期
Phase 2 study of BK1304 in healthy childrePrevention of influenzaJPRN-jRCT2031200156Fuji Hideyuki120
未知
2 期
Safety of BK1301 in healthy adultsDiphtheria, Tetanus, Pertussis preventionJPRN-jRCT2080222663The Research Foundation for Microbial Diseases of Osaka University20
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphomaMedDRA version: 16.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-DEovartis Pharma Services AG66
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractorydiffuse large B-cell lymphoma, mantle cell lymphoma and follicularlymphomaDiffuse large B-cell lymphoma, Mantle cell lymphoma and FollicularlymphomaMedDRA version: 14.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-ESovartis Farmacéutica S.A.66